Conclusions:
The results suggest that more patients with a target set at baseline are in remission at 12 months and at 24 months than those without a target set. Number of visits, number of DAS28 scores and starting dual therapy within 6 months do not appear to affect the proportion of patients in remission at 12 months, but active management in the first 12 months (>4 visits, >4 DAS28 scores) does appear to be associated with more patients in remission at 24 months. Thus we conclude that treating RA early and aggressively, in line with the T2T guidelines, leads to sustained clinical improvement. Methods: Data from a 1yr interim analysis of the ECLAIR study were used: a longitudinal, prospective, observational, multicentre study of pts with RA starting treatment with certolizumab pegol (CZP) in France. Pts were evaluated at study entry and thereafter at 3-monthly routine consultations. Disease activity was assessed at each visit using CDAI, DAS28 and HAQ-DI. At Wk12, pts with missing data or no longer taking CZP were excluded from the analyses. Linear interpolation, LOCF or NRI were used to impute missing data at 1yr, including data from pts who left the study early. Different definitions for treatment non-response were applied based on CDAI or DAS28 and HAQ-DI relative to pre-treatment values. Non-response at Wk12 was defined as CDAI>10, DAS28<1.2 or HAQ-DI<0.22. Then, failure at 1yr was defined as CDAI>22, DAS28>3.2 and HAQ-DI>0.5. Positive predictive values (PPV; proportion of treatment failures at 1yr in Wk12 non-responders) were used to evaluate the predictive performance of each tool. Results: Overall, 792 pts were enrolled and data from 730 pts analysed. Performance of CDAI at predicting treatment failure at 1yr was assessed in 532 pts (198 data values missing at Wk12). Response and failure rates at Wk12 and 1yr are presented (see Table) . The PPV for CDAI was 88.8%, indicating that almost 9/10 pts identified as non-responders at Wk12 fail to respond at 1yr. Specificity was also high (96.0%), indicating that <5% of pts who achieved CDAI response at 1yr were non-responders at Wk12. Similar analyses performed for DAS28 and HAQ-DI produced PPVs of 69.0% and 75.4%, respectively.
The PPV describing the performance of early CDAI measure as a
